Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 744 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: oral dexamethasone Clear all
Recruiting Phase 1 Interventional

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT05581030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01088763
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

NCT01054144
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Prednisone, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

NCT01640340
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
aprepitant, palonosetron hydrochloride, ondansetron, dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

NCT04606264
View directory record Official record
Conditions
Perioperative Optimization
Interventions
Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1
Drug
Lead sponsor
Jennifer Holder-Murray
Other
Eligibility
18 Years and older
Enrollment
3,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Not yet recruiting Phase 2 Interventional

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

NCT00724568
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Doxil
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

NCT06930651
View directory record Official record
Conditions
Myeloid Malignancies
Interventions
Dexamethasone, Cyclophosphamide, Fludarabine, Decitabine, TGFBR2 KO CAR27/IL-15 NK cells
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

NCT06428630
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Reaction
Interventions
dexamethasone oral rinse
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

NCT00553059
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dexamethasone, dronabinol, palonosetron hydrochloride, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Springfield, Missouri • Greenville, South Carolina • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 3 Interventional

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

NCT07772024
View directory record Official record
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
InoPd, Investigator's choice of SAT
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Durham, North Carolina • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 22, 2026, 4:53 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy

NCT05200806
View directory record Official record
Conditions
Analgesia, Post-Operative Pain, Breakthrough Pain, Colectomy
Interventions
Non-Narcotic ERAS Post-Operative Pain Management
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 22, 2026, 4:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate
Drug · Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Individualizing Corticosteroid Use in Pneumonia

NCT05334316
View directory record Official record
Conditions
Pneumonia
Interventions
Dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional Results available

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00687674
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, sorafenib tosylate, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 22, 2026, 4:53 AM EDT
Not listed Phase 1 Interventional

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

NCT04519476
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
Selinexor, Lenalidomide, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

NCT00890656
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide (CTX), Vincristine, Doxorubicin, Decadron, G-CSF, Methotrexate (MTX), Ara-C, Pegaspargase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

NCT06892522
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
15
States / cities
Duarte, California • Irvine, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 3 Interventional

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Interventions
Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
63
States / cities
Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

NCT00507416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
234
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT02103335
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
Interventions
pomalidomide, marizomib, low-dose dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 22, 2026, 4:53 AM EDT